Document is current
Any future updates will be listed below
-
Authors
Yiangou, Andreas https://orcid.org/0000-0001-8905-5734
Mitchell, James L.
Nicholls, Matthew
Chong, Yu Jeat
Vijay, Vivek https://orcid.org/0000-0002-6843-5532
Wakerley, Benjamin R. https://orcid.org/0000-0003-1016-5207
Lavery, Gareth G. https://orcid.org/0000-0001-5794-748X
Tahrani, Abd A. https://orcid.org/0000-0001-9037-1937
Mollan, Susan P. https://orcid.org/0000-0002-6314-4437
Sinclair, Alexandra J. https://orcid.org/0000-0003-2777-5132
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02124486 at ClinicalTrials.govDocuments that mention this clinical trial
Randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of idiopathic intracranial hypertension: the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT) protocol
https://doi.org/10.1136/bmjopen-2017-017426
Obstructive sleep apnoea in women with idiopathic intracranial hypertension: a sub-study of the idiopathic intracranial hypertension weight randomised controlled trial (IIH: WT)
https://doi.org/10.1007/s00415-021-10700-9
-
Funding
Funding for this research was provided by:
National Institute for Health Research (NIHR-CS-011-028, NIHR-CS-2013-13-029)
Medical Research Council (MR/K015184/1)
Wellcome Trust (104612/Z/14/Z)
Sir Jules Thorn Charitable Trust (Award for Biomedical Science)
- License Information
-
More Information
Article History
Received: 4 June 2021
Revised: 2 July 2021
Accepted: 3 July 2021
First Online: 22 August 2021
Declarations
:
: Nicholls, Chong, Vijay, Lavery have no conflicts of interest to declare that are relevant to the content of this article. Yiangou reports receiving speaker fees from Teva, UK outside the submitted work. Mitchell reports receiving grants from the National Institute of Health Research during the conduct of the study and grants from the UK Ministry of Defence outside the submitted work. Wakerley reports receiving consultancy fees from Invex Therapeutics outside the submitted work. Lavery reports receiving funding through a Wellcome Trust Senior Fellowship during the conduct of the study. Mollan reports receiving personal fees from Allergan, Chiesi Farmaceutici, Heidelberg Engineering, Invex Therapeutics, Neurodiem, Novartis, Roche, Santen Pharmaceutical, Scope Ophthalmics and Santhera Pharmaceuticals outside the submitted work. Tahrani reports grants, personal fees, and travel support from Sanofi, grants, personal fees and educational events grants from Novo Nordisk, travel support from Merck Sharp and Dohme, personal fees and travel support from Boehringer Ingelheim, personal fees from Lilly, AstraZeneca, Bristol-Myers Squibb, and Janssen, equipment and travel support from ResMed, equipment from Philips Resporinics, Impeto Medical, and ANSAR Medical Technologies, grants and non-financial support from Napp, and equipment and support staff from BHR Pharmaceuticals Ltd. Tahrani is currently an employee of Novo Nordisk. This work was performed before Tahrani becoming a Novo Nordisk employee and Novo Nordisk had no role in this study. Sinclair reports receiving personal fees (salary and stock options) from Invex therapeutics, during the conduct of the study but outside the submitted work; and receiving grants from the Medical Research Council of the United Kingdom and funding through a Sir Jules Thorn Award for Biomedical Science during the conduct of the study.
: The National Research Ethics Committee West Midlands – The Black Country approved IIH: WT (14/WM/0011). The study was conducted according to the Declaration of Helsinki.
: Informed written consent was obtained from all individual participants included in the study.
